Unmistakable Upward Trend<br />By Rev Shark<br />RealMoney.com Contributor<br />10/15/2009 8:37 AM EDT<br /><br /> "Skepticism is unbelief in cause and effect."<br /><br /> -- Ralph Waldo Emerson <br /><br />Goldman Sachs' (GS) earnings are out this morning and are well ahead of published expectations but apparently don't beat the whisper number. The stock is trading down a little over $5, but you can bet there will be plenty of traders looking for a chance to buy on the weakness.<br /><br />After yesterday's DJIA 10,000 celebration and the surprisingly good earnings reports from Intel (INTC) and JPMorgan Chase (JPM) many seem to be prepared for the market to just keep on steadily improving. The fact that we've already come so far from the March lows is an irrelevancy to many, and the attitude among some is that things are now improving so fast that you would be foolish to even be thinking about selling.<br /><br />That sort of sentiment is a little troubling, and we'll have to keep on eye on how frothy the bulls become, but the big advantage the bulls have is that there are still far too many folks who have never been able to embrace the positives in market. They have been fighting it for many months now, are underinvested and are convinced it is all just a matter of time before we see a nasty correction.<br /><br />As we keep going up and up, these skeptics are slowly drawn into the market, not because they are true believers and really want to buy but because they are pragmatic and are hoping to make some money while the rest of the world is acting so crazy. They don't plan to stick around. They are skeptics and are keeping their fingers on the eject button, but if the fools are going to keep on buying, they we will go along for the ride. The end result is one of the most hated bull markets I have ever seen.<br /><br />Luckily for the bulls, they have tremendous momentum going for them -- good earnings news; anxious, underinvested bulls ready to buy dips; and a lot of cheerleading. We even had a Dow 10,000 special last night, which I think was a repeat of something we saw about 10 years ago.<br /><br />We can sit here and try to be critical of this market and the bulls that love it. It isn't hard to make a case for why such strength is so irrational. The fundamental arguments about the economy are easy to make, and only extreme optimists wouldn't wonder a little bit if maybe the market has run ahead of the economy<br /><br />Nonetheless, the trend is unmistakable and is straight up. We might be cute and try to catch some quick pullback because conditions are overextended, but it is very dangerous game to play. There is just too much money out there looking for a place to go, and with the potential of good earnings for the next few weeks, it is the bulls who are in control.<br /><br />Citigroup's (C) earnings are now out, and while its numbers are ahead, the reaction is some selling. Don't forget we have the mighty Google (GOOG) and International Business Machines (IBM) reporting tonight, so there is going to be plenty of reasons for the bulls to remain optimistic.<br /><br />As you consider the action, keep in mind that while there are plenty of reasons to not like this market, there are very few good reasons to fight the strength.<br /><br />We are a little soft in the early going, but this market consistently has come back from the early pressure. With IBM and Google on the agenda tonight, I don't think that the optimism is going to disappear too fast. <br />-----------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: DSW +10.0% (light volume), GTN +5.5%, WDFC +5.4%, APH +4.6% (light volume), AVGO +3.2%, UMPQ +1.9%... M&A news: RUBO +26.8% (Rubio's receives an unsolicited letter outlining a proposal to acquire all outstanding common stock for $8.00 per share)... Select drug related names showing strength: SHPGY +2.4%, GSK +2.3%, NVS +1.0%... Select communcations/telecom related names trading higher: RVSN +3.9%, BT +2.7%, VOD +2.0%... Other news: ACOR +55.3% (announces positive vote by FDA Advisory Committee for Fampridine-SR; also upgraded to Buy at Merriman and upgraded to Outperform at Baird), SLTM +36.2% (announces FDA 510(k) Clearance of new Fraxel restore dual laser system), CLSN +14.0% (Celsion's Global Phase III ThermoDox trial approved by SFDA in China), PLX +9.2% (announces positive top-line results from its Ph. III clinical trial for UPLYSO for treatment of Gaucher Disease), THLD +8.1% (licenses Glufosfamide to Eleison Pharmaceuticals), APSG +3.6% (Cramer makes positive comments on MadMoney), BTI +2.5% (still checking), CBY +1.8% (still checking), BP +1.8% (still checking for anything specific), LYG +1.0% (Lloyds TSB talks with Rathbone on investment management assets - DJ)... Analyst comments: SPWRA +1.1% (upgraded to Outperform at Baird).<br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: MNI -10.4%, NOK -8.0%, DTLK -4.3% (light volume), , HOG -3.9%, CY -3.7%, BAX -3.5%, FCS -3.3%, SCHW -2.7% (downgraded to Neutral from Buy at BofA/Merrill), PPG -2.5%, SPTN -2.4%, C -2.4%, ATR -2.3%, GS -2.2%, XLNX -2.1%, CCK -2.0%... Select financial names showing weakness: AIB -5.0%, COF -4.1%, AZ -2.5%, MS -2.1%, BBV -1.7%, CS -1.6%, NMR -1.4%, JPM -1.2%, WFC -1.1%... Select metals/mining names pulling back: GSS -3.7%, NG -3.1%, CDE -2.9%, ABX -1.9%, SLV -1.7%, GG -1.7%, MT -1.2%... Select casino related names trading lower: LVS -5.2%, MPEL -4.4%, MGM -3.4%, WYNN -2.9%... Other news: GKK -7.1% (still checking), DGIT -3.1% (files for 4.5 mln share common stock offering and $25 mln preferred stock offering), VIA.B -2.3% (prices 19,382,945 VIA.B common shares offered by National Amusements at $28.25/share), CBS -2.3% (prices 26,040,909 common shares sold BY NAIRI at $12/share), BJS -2.2% (receives second request under US Antitrust Review; downgraded to Sell at Citigroup), BHI -1.9% (receives second request under US Antitrust Review; downgraded to Sell at Citigroup), LAZ -0.9% (WSJ reports CEO Bruce Wasserstein has died)... Analyst comments: HST -3.5% (downgraded to Underperform at Baird), LRCX -2.6% (downgraded to Sell from Hold at Citigroup), SII -1.9% (initiated with Underperform at BMO), TRV -1.4% (downgraded to Mkt Perform at Keefe Bruyette), KMP -1.3% (downgraded to Mkt Perform at Oppenheimer), ASML -1.0% (downgraded to Sell at Citigroup).